WO1998055114A1 - Composition pour le traitement de l'osteoporose et pour favoriser la reparation des fractures osseuses contenant du calcium, de la vitamine d et des acides amines - Google Patents
Composition pour le traitement de l'osteoporose et pour favoriser la reparation des fractures osseuses contenant du calcium, de la vitamine d et des acides amines Download PDFInfo
- Publication number
- WO1998055114A1 WO1998055114A1 PCT/CH1998/000237 CH9800237W WO9855114A1 WO 1998055114 A1 WO1998055114 A1 WO 1998055114A1 CH 9800237 W CH9800237 W CH 9800237W WO 9855114 A1 WO9855114 A1 WO 9855114A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- calcium
- vitamin
- amino acids
- composition
- proportion
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Definitions
- the present invention relates to a composition, in particular for the preparation of a medicament for the treatment of osteoporosis and / or for promoting the repair of bone fractures, said composition containing calcium and vitamin D.
- the bones have mainly two constituents, namely: a) hydroxyapatite constituted by calcium salts and phosphates, b) the organic matrix constituted largely by collagen fibers which is a complex substance having in its structure amino acids and sugars.
- osteoporosis which is the most common bone disorder in adulthood, especially in women after menopause, and the most common cause of bone fractures in people. elderly.
- the repair of common bone fractures, as well as those associated with osteoporosis, requires that the neoformation of the bone be preponderant as that which characterizes the period of growth. If this process does not take place, there is a delay or an impediment to repair called
- a hyper-protein diet would seem to be the best appropriate precaution to satisfy this last requirement, but, unfortunately, it does not cause the desired effect. On the contrary, it causes demineralization of the bone due to an increased urinary excretion of calcium as specified by the authors below in their publications. (Allen, 1982, Hergsted 1986, Hergsted and Linkswillwer, 1981).
- Pyro-phosphate analogs are promising agents, but also in this case, the prolongation in time of their therapeutic action is doubtful.
- compositions based on calcium and amino acids intended to improve the effective absorption of calcium by the human body, to increase its deposition on the bones and, therefore, to limit the effects of osteoporosis.
- the present invention proposes to overcome the drawbacks and deficiencies of previous treatment methods by providing a composition which makes it possible to ensure rapid and lasting reconstruction of bone tissue after a fracture or following osteoporosis attacks.
- composition according to the invention as defined in preamble, characterized in that it also comprises amino acids the proportion of which relative to said calcium and vitamin D is equal to the proportion of amino acids relative to calcium and vitamin D present in the organic matrix of human bone tissue.
- the proportion of calcium gluconate present is less than or equal to 6% by weight, the proportion of calcium heptagluconate present is substantially equal to 7.5% by weight and the proportion of vitamin D3 present is equal to 0.0005% o by weight.
- the composition is packaged for administration by the oral route, in the form of a solution, of capsules, granules, powders, capsules or the like.
- a food integrator characterized in that it comprises a composition as claimed, in particular for the preparation of a medicament for the treatment of osteoporosis and / or for promoting the repair of bone fractures.
- the composition is in the form of a solution and is administered orally, to doses of 40 to 50mg / kg of body weight. It is found that it manifests the desired effect, without producing the demineralization that is usually observed when the amino acids necessary for bone formation are introduced into the body through hyper-protein diets.
- composition can advantageously be presented in the form of a solution contained in 10 ml vials further containing a flavoring agent and a preservative. Its composition is preferably as follows:
- Second group ovariectomized with a diet with calcium deficiency.
- the doses of calcium and vitamin D are of the same order as those used in several food integrators present on the market. Also because of this, the composition is perfectly tolerated by patients.
- mice of both sexes using the Irwin (x) method which allows the qualitative and quantitative recording of alterations at the charge of various functions, such as the diameter of the pupil, salivary and lacrimal secretions , tone and motor coordination, reactivity to external stimuli.
- various functions such as the diameter of the pupil, salivary and lacrimal secretions , tone and motor coordination, reactivity to external stimuli.
- the composition did not generate any variation in the functions considered.
- Clinical studies were subsequently carried out.
- the first was conducted on twenty women, between the ages of 60 and 70, suffering from osteoporosis diagnosed on the basis of clinical symptoms and laboratory data, and still not treated with other drugs.
- the patients were divided into two homogeneous groups which were treated respectively with the composition according to the invention as regards the first group and with calcium and vitamin D at the same doses as regards the second group.
- the compositions were administered orally, twice a day before meals.
- the patients were kept under observation for six months, subjected each month to a control of clinical manifestations such as joint pain, difficulty in wandering, etc., and also subjected to the standard examination for determination of bone density and to determination of urinary calcium excretion.
- the subjects were divided into two homogeneous groups, one of which was treated with the composition according to the invention at the rate of twice-daily administration, and the other with a composition containing only calcium and vitamin D, in amounts equal to those contained in the composition of the invention.
- composition when administered to humans at a daily dose (in two doses) corresponding to the ingestion of 3.5 to 4 g of amino acids present in the organic matrix of l he human bone has a favorable effect both for the treatment of osteoporosis and to promote the welding of common bone fractures.
- the data obtained in animals demonstrate that the presence of calcium and vitamin D in the composition is useful in achieving the desired effect.
Landscapes
- Health & Medical Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11501221A JP2001500161A (ja) | 1997-06-04 | 1998-06-03 | カルシウム、ビタミンd及びアミノ酸を含有し、骨粗鬆症の処置のための、そして破損骨治療を促進するための組成物 |
EP98921326A EP0920308A1 (fr) | 1997-06-04 | 1998-06-03 | Composition pour le traitement de l'osteoporose et pour favoriser la reparation des fractures osseuses contenant du calcium, de la vitamine d et des acides amines |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR97/07081 | 1997-06-04 | ||
FR9707081A FR2764191A1 (fr) | 1997-06-04 | 1997-06-04 | Preparation pour le traitement de l'osteoporose et pour favoriser la reparation des fractures osseuses |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998055114A1 true WO1998055114A1 (fr) | 1998-12-10 |
Family
ID=9507733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CH1998/000237 WO1998055114A1 (fr) | 1997-06-04 | 1998-06-03 | Composition pour le traitement de l'osteoporose et pour favoriser la reparation des fractures osseuses contenant du calcium, de la vitamine d et des acides amines |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0920308A1 (fr) |
JP (1) | JP2001500161A (fr) |
CA (1) | CA2260861A1 (fr) |
FR (1) | FR2764191A1 (fr) |
WO (1) | WO1998055114A1 (fr) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001158736A (ja) * | 1999-11-30 | 2001-06-12 | Snow Brand Milk Prod Co Ltd | 骨関節疾患の予防及び改善剤 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05161480A (ja) * | 1991-10-14 | 1993-06-29 | Fujitsukusu Kk | アミノ酸を配合したカルシウム組成物およびそれを含有するカルシウム飲料 |
US5296246A (en) * | 1991-08-08 | 1994-03-22 | Fujix Corporation | Active amino acid Ca, beverages containing same, and process for their production |
-
1997
- 1997-06-04 FR FR9707081A patent/FR2764191A1/fr not_active Withdrawn
-
1998
- 1998-06-03 CA CA002260861A patent/CA2260861A1/fr not_active Abandoned
- 1998-06-03 WO PCT/CH1998/000237 patent/WO1998055114A1/fr not_active Application Discontinuation
- 1998-06-03 JP JP11501221A patent/JP2001500161A/ja active Pending
- 1998-06-03 EP EP98921326A patent/EP0920308A1/fr not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5296246A (en) * | 1991-08-08 | 1994-03-22 | Fujix Corporation | Active amino acid Ca, beverages containing same, and process for their production |
JPH05161480A (ja) * | 1991-10-14 | 1993-06-29 | Fujitsukusu Kk | アミノ酸を配合したカルシウム組成物およびそれを含有するカルシウム飲料 |
Non-Patent Citations (2)
Title |
---|
DATABASE WPI Section Ch Week 9330, Derwent World Patents Index; Class B05, AN 93-239245, XP002054172 * |
GENNARI C ET AL: "ROLE OF NUTRITION IN THE PATHOGENESIS OF OSTEOPOROSIS", FABRIS, F., L. PERNIGOTTI AND E. FERRARIO (ED.). AGING (NEW YORK), VOL. 38. SEDENTARY LIFE AND NUTRITION. XII+204P. RAVEN PRESS: NEW YORK, NEW YORK, USA. ILLUS. ISBN 0-88167-730-2., 0 (0). 1990. 109-118., XP002054171 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001158736A (ja) * | 1999-11-30 | 2001-06-12 | Snow Brand Milk Prod Co Ltd | 骨関節疾患の予防及び改善剤 |
Also Published As
Publication number | Publication date |
---|---|
FR2764191A1 (fr) | 1998-12-11 |
EP0920308A1 (fr) | 1999-06-09 |
JP2001500161A (ja) | 2001-01-09 |
CA2260861A1 (fr) | 1998-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2328730C (fr) | Traitement de l'hypertension iatrogene et liee au vieillissement et compositions pharmaceutiques utiles a cet effet | |
FR2774591A1 (fr) | Composition pharmaceutique comprenant l'association metformine et fibrate et son utilisation pour la preparation de medicaments destines a reduire l'hyperglycemie | |
FR2629716A1 (fr) | Composition pharmaceutique pour administration orale a base d'un derive d'acide diphosphonique | |
LU88323A1 (fr) | Comprimes solubles dans l'eau | |
CZ293735B6 (cs) | Farmaceutický prostředek pro léčbu plicní nemoci | |
JP2001509173A (ja) | 胃腸リパーゼ阻害剤の使用 | |
FR2604359A1 (fr) | Medicament a liberation controlee pour fournir des ions fluorure | |
JP2004534094A (ja) | 二日酔いに有効な組成物及びそのための使用 | |
NZ506020A (en) | Use of pharmaceutical combinations containing tramadol and an antiemetic | |
HU228109B1 (en) | The use of phospholipid complexes of vitis vinifera extracts for producing medicaments as anti-atherosclerotic agents | |
FR2530469A1 (fr) | Composition analgesique et anti-inflammatoire contenant de la cafeine | |
FR2604360A1 (fr) | Medicament a liberation controlee pour fournir des ions fluorure | |
JPH0699310B2 (ja) | アセトアルデヒド解毒剤 | |
JPH01261334A (ja) | アンギオテンシン転換酵素阻害剤を有効成分とした医療用調剤及びその製造方法 | |
WO1998055114A1 (fr) | Composition pour le traitement de l'osteoporose et pour favoriser la reparation des fractures osseuses contenant du calcium, de la vitamine d et des acides amines | |
FR2628321A1 (fr) | Medicament pour le traitement de l'osteoporose | |
EP1117410B1 (fr) | Utilisation de derives de l'acide bisphosphonique pour la preparation d'un medicament destine au traitement des boiteries | |
WO1992022305A1 (fr) | Composition therapeutique pour liberation prolongee de magnesium | |
WO1996017616A1 (fr) | Trousse pour cycle de traitement de l'osteoporose | |
FR2845916A1 (fr) | Composition pharmaceutique associant le tenatoprazole et un antagoniste des recepteurs h2 a l'histamine | |
EP1661575A1 (fr) | Utilisation de magnésium dans le traitement des troubles associés aux variations hormonales chez la femme | |
EP0758245B1 (fr) | Utilisation de la spiramycine dans des desordres gastrointestinaux dus a h. pyroli | |
WO2023156275A1 (fr) | Composition pharmaceutique et médicament comprenant du l-tryptophane, du l-5-hydroxytryptophane et un inhibiteur de dégradation périphérique | |
LU87777A1 (fr) | Nouvelle forme galenique orale ameliorant la biodisponibilite | |
FR2733911A1 (fr) | Composition pharmaceutique pour maladies renales ou cardio-vasculaires |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1998921326 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2260861 Country of ref document: CA Kind code of ref document: A Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09230904 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 1999 501221 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWP | Wipo information: published in national office |
Ref document number: 1998921326 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1998921326 Country of ref document: EP |